Impel Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
Impel Pharmaceuticals (NASDAQ: IMPL) announced a live webcast on November 14, 2022, at 8:30 a.m. ET to disclose its third-quarter 2022 financial results and provide a business update.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Impel Pharmaceuticals (NASDAQ: IMPL) announced a live webcast on November 14, 2022, at 8:30 a.m. ET to disclose its third-quarter 2022 financial results and provide a business update. The webcast can be accessed through the company’s investor website. Impel is focused on creating transformative therapies for diseases with high unmet medical needs, including Trudhesa® for treating migraines and INP105 for managing agitation in autism patients.
Positive
- Plans to report third-quarter 2022 financial results could signal transparency and investor engagement.
- Development of INP105 for autism adds potential growth avenues in underserved markets.
Negative
- None.
Details
News Market Reaction – IMPL
The recorded move for IMPL in the trading session of this news was +3.39%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Monday, November 14, 2022, at 8:30 a.m. ET to report its third quarter 2022 financial results and provide a business update.
To access the live conference call, please register using the conference link: https://register.vevent.com/register. A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/. A replay of the webcast and accompanying slides will be available on the Impel Pharmaceuticals website following the event.
About Impel Pharmaceuticals
Impel Pharmaceuticals is a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs. Impel offers and is developing treatments that pair its proprietary POD® technology with well-established therapeutics. In addition to Trudhesa® nasal spray, which is approved in the U.S. for the acute treatment of migraine with or without aura in adults. Impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism.
For additional information about Impel, please visit www.ImpelPharma.com
Contact:
Media Relations
Melyssa Weible
Elixir Health Public Relations
Phone: (1) 386-366-0616
Email: mweible@elixirhealthpr.com
Investor Relations
Christina Tartaglia
Stern Investor Relations
Phone: 212-362-1200
Email: christina.tartaglia@sternir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.